EMA announces launch of collaborative pilot scheme to inspect manufacturers
The EMA will collaborate with other medicine regulatory bodies globally in a pilot programme to inspect sterile medicine manufacturers.
List view / Grid view
The EMA will collaborate with other medicine regulatory bodies globally in a pilot programme to inspect sterile medicine manufacturers.
Partnering for product characterisation can streamline drug development and create efficiencies in moving from concept to clinic.
The FDA has announced that a notice of proposed rulemaking has been issued that would allow for the importation of certain prescription drugs from Canada which could lead to lower prescription drug prices.
Vapour-compression-based WFI production has a total cost of ownership that is less than or equivalent to that of a membrane-based system and significantly less than that of a typical multiple-effect-based system. The following whitepaper provides examples that illustrate system designs that are relatively basic, yet typically sufficient.
Cannabinoids are of growing interest in the pharmaceutical industry. Mark Tucker explains how this class of compounds is viewed across the world and why regulations surrounding them hinder their progress, yet remain necessary.
University of Leeds researchers have discovered a method to produce polio vaccines made from virus-like particles, which is being trialled on a manufacturing platform.
An additional 6,000m2 of cell and gene therapy manufacturing space is expected to become available within the next 12 months, according to new data.
The Philippines’ 2019 Universal Health Care Act and regulatory tax reforms open new avenues for the Indian pharmaceutical industry, according to new research.
A study has revealed that in industrialising and urbanising countries, pharmaceutical pollution in rivers could lead to antimicrobial resistance.
In the wake of Brexit, the pharma industry will need to respond to a new regulatory landscape. Peter Morgan discusses how businesses have to prepare for the oncoming political changes, all whist retaining high pharmaceutical product quality.
Industrial transformation is a very real phenomenon. Companies are going beyond standard practices to seek out step-change improvement in industrial operations, with several companies already reporting "dramatic results".
A recent industry report projects a boom in the biosimilars market over the next three years and highlights key considerations for meeting its potential.
The US National Academies of Sciences, Engineering, and Medicine have released a report that suggests regulators need to collaborate more to ensure drug quality.
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
Some pharmaceutical manufacturers can struggle to keep microorganisms away from their facilities, which sometimes goes unnoticed until it is too late. While there are numerous threatening microorganisms, this article focuses on some of the most troublesome, highlighting the hazards they pose and analysing how manufacturers can prevent microbial contamination in…